Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

Pierre D. Delmas, Silvano Adami, Cezary Strugala, Jacob A. Stakkestad, Jean Yves Reginster, Dieter Felsenberg, Claus Christiansen, Roberto Civitelli, Marc K. Drezner, Robert R. Recker, Michael Bolognese, Claire Hughes, Daiva Masanauskaite, Penelope Ward, Philip Sambrook, David M. Reid

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Objective. Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis. Methods. In a randomized, double-blind, double-dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 mg every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55-80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2-L4] bone mineral density [BMD] T score less than -2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C-telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability. Results. At 1 year, mean lumbar spine BMD increases were as follows: 5.1% among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8% among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8% among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior (P <0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function. Conclusion. As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated.

Original languageEnglish
Pages (from-to)1838-1846
Number of pages9
JournalArthritis and Rheumatism
Volume54
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Intravenous Injections
Intravenous Administration
Osteoporosis
Bone Density
Diphosphonates
Pelvic Bones
Spine
ibandronic acid
Collagen Type I
Serum
Vitamin D
Nitrogen
Calcium
Kidney
Safety

All Science Journal Classification (ASJC) codes

  • Immunology
  • Rheumatology

Cite this

Delmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J. Y., Felsenberg, D., ... Reid, D. M. (2006). Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis and Rheumatism, 54(6), 1838-1846. https://doi.org/10.1002/art.21918

Intravenous ibandronate injections in postmenopausal women with osteoporosis : One-year results from the dosing intravenous administration study. / Delmas, Pierre D.; Adami, Silvano; Strugala, Cezary; Stakkestad, Jacob A.; Reginster, Jean Yves; Felsenberg, Dieter; Christiansen, Claus; Civitelli, Roberto; Drezner, Marc K.; Recker, Robert R.; Bolognese, Michael; Hughes, Claire; Masanauskaite, Daiva; Ward, Penelope; Sambrook, Philip; Reid, David M.

In: Arthritis and Rheumatism, Vol. 54, No. 6, 06.2006, p. 1838-1846.

Research output: Contribution to journalArticle

Delmas, PD, Adami, S, Strugala, C, Stakkestad, JA, Reginster, JY, Felsenberg, D, Christiansen, C, Civitelli, R, Drezner, MK, Recker, RR, Bolognese, M, Hughes, C, Masanauskaite, D, Ward, P, Sambrook, P & Reid, DM 2006, 'Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study', Arthritis and Rheumatism, vol. 54, no. 6, pp. 1838-1846. https://doi.org/10.1002/art.21918
Delmas, Pierre D. ; Adami, Silvano ; Strugala, Cezary ; Stakkestad, Jacob A. ; Reginster, Jean Yves ; Felsenberg, Dieter ; Christiansen, Claus ; Civitelli, Roberto ; Drezner, Marc K. ; Recker, Robert R. ; Bolognese, Michael ; Hughes, Claire ; Masanauskaite, Daiva ; Ward, Penelope ; Sambrook, Philip ; Reid, David M. / Intravenous ibandronate injections in postmenopausal women with osteoporosis : One-year results from the dosing intravenous administration study. In: Arthritis and Rheumatism. 2006 ; Vol. 54, No. 6. pp. 1838-1846.
@article{21e31e18dac44405b6d88a4fe63dabf4,
title = "Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study",
abstract = "Objective. Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis. Methods. In a randomized, double-blind, double-dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 mg every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55-80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2-L4] bone mineral density [BMD] T score less than -2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C-telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability. Results. At 1 year, mean lumbar spine BMD increases were as follows: 5.1{\%} among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8{\%} among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8{\%} among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior (P <0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function. Conclusion. As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated.",
author = "Delmas, {Pierre D.} and Silvano Adami and Cezary Strugala and Stakkestad, {Jacob A.} and Reginster, {Jean Yves} and Dieter Felsenberg and Claus Christiansen and Roberto Civitelli and Drezner, {Marc K.} and Recker, {Robert R.} and Michael Bolognese and Claire Hughes and Daiva Masanauskaite and Penelope Ward and Philip Sambrook and Reid, {David M.}",
year = "2006",
month = "6",
doi = "10.1002/art.21918",
language = "English",
volume = "54",
pages = "1838--1846",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Intravenous ibandronate injections in postmenopausal women with osteoporosis

T2 - One-year results from the dosing intravenous administration study

AU - Delmas, Pierre D.

AU - Adami, Silvano

AU - Strugala, Cezary

AU - Stakkestad, Jacob A.

AU - Reginster, Jean Yves

AU - Felsenberg, Dieter

AU - Christiansen, Claus

AU - Civitelli, Roberto

AU - Drezner, Marc K.

AU - Recker, Robert R.

AU - Bolognese, Michael

AU - Hughes, Claire

AU - Masanauskaite, Daiva

AU - Ward, Penelope

AU - Sambrook, Philip

AU - Reid, David M.

PY - 2006/6

Y1 - 2006/6

N2 - Objective. Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis. Methods. In a randomized, double-blind, double-dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 mg every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55-80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2-L4] bone mineral density [BMD] T score less than -2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C-telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability. Results. At 1 year, mean lumbar spine BMD increases were as follows: 5.1% among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8% among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8% among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior (P <0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function. Conclusion. As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated.

AB - Objective. Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis. Methods. In a randomized, double-blind, double-dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 mg every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55-80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2-L4] bone mineral density [BMD] T score less than -2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C-telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability. Results. At 1 year, mean lumbar spine BMD increases were as follows: 5.1% among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8% among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8% among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior (P <0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function. Conclusion. As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=33745034449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745034449&partnerID=8YFLogxK

U2 - 10.1002/art.21918

DO - 10.1002/art.21918

M3 - Article

C2 - 16729277

AN - SCOPUS:33745034449

VL - 54

SP - 1838

EP - 1846

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 6

ER -